Background. During a World Health Organization-convened Guideline Development Group meeting, recommendations for postexposure prophylaxis (PEP) for human immunodeficiency virus were made and research gaps identified.
In June 2014, the World Health Organization (WHO) revised the global evidence-based recommendations for the use of antiretrovirals for postexposure prophylaxis (PEP) to prevent human immunodeficiency virus (HIV) transmission in the light of current evidence [1] . The process was supported by a Guideline Development Group (GDG) of experts in the field who reviewed evidence from key systematic reviews to formulate new recommendations for drug choice, prescribing methods, and clinical management. An essential component of any systematic review, as well as guideline development, is the identification of key research gaps. In this article, we present potential approaches for the conduct of future HIV PEP research to overcome feasibility or practical challenges that may arise. We demonstrate how the Grading of Evidence, Assessment, Development and Evaluation (GRADE) system can be used effectively as a conceptual framework and tool beyond the determination and qualification of recommendations to identify future research priorities and methodological challenges for research.
GRADE System
WHO has adopted the GRADE system for the development of global clinical, programmatic, and public health guideline recommendations [2] . The GRADE system allows for the explicit use of factors that can increase or decrease the quality of the evidence from a starting point determined by study design [3] . In addition to appraising the quality of evidence, the GRADE approach includes an assessment of potential benefits and harms, resource utilization, and user values and preferences. The GDG considers these elements together to determine the direction and strength of a recommendation.
METHODS
Each recommendation made by the WHO HIV PEP GDG (see Acknowledgements) was driven by an a priori clinical or programmatic question that was identified along the clinical management pathway for HIV PEP (Figure 1) . A systematic review conducted for each question and GRADE Evidence Profile tables summarizing the overall quality of evidence from each systematic review were presented to the GDG. The GDG subsequently formulated a recommendation and determined the strength of each recommendation.
For each stage on the clinical management pathway, we tabulated the following: (1) the clinical or programmatic question; (2) the recommendation formulated by the GDG or a record that no recommendation was made; (3) the strength of each recommendation where applicable; (4) the quality of evidence underpinning the recommendation; (5) the most appropriate study design to answer the research question; (6) conceptualization of a pragmatic alternative study design if the ideal design was not feasible; and (7) consideration of the methodological challenges of the study design with the potential bias(es) identified.
In addition to making recommendations, the GDG experts also considered the clinical management pathway of HIV PEP and additional associated research gaps. Table 1 provides an overview of future PEP research priorities and the study design(s) considered most feasible to answer each clinical or programmatic question. Overall, 3 key study design formats were identified to address 12 questions: (1) surveyand interview-driven research to identify barriers to access to PEP and related clinical care; (2) establishment of a global PEP registry to generate data to inform the choice of an optimal PEP drug regimen, to record drug toxicities arising from specific PEP regimens, and to track follow-up and linkage to care (including transition from PEP to preexposure prophylaxis [PrEP]); and (3) randomized controlled trials (RCTs) to determine the optimal adherence promotion strategies necessary for successful outcomes following PEP.
RESULTS

DISCUSSION
We applied the GRADE framework to enhance the identification and description of the most appropriate and feasible research required to strengthen the evidence base for current and future PEP recommendations. By taking into account both quality of the available evidence and the strength of current recommendations, we were able to clearly identify research gaps. Where recommendations had not been made, expert knowledge of the PEP clinical management pathway allowed the GDG to formulate key research questions and identify the necessary study design. The generation of new data to inform PEP guidelines is challenged by the specific circumstances of the clinical encounter. HIV transmission is a low-probability event (because of biological and behavioral cofactors) and a high-consequence outcome for the affected individual [4] . Hence, PEP administration is often done in emergency settings, with high levels of anxiety expressed by those who present for PEP. Yet, because of the low average per-contact HIV risk, people who do not take PEP, or who initiate treatment but are nonadherent, and who only sustain a discrete high-risk exposure are not likely to become HIV infected. The relative inefficiency of HIV transmission for the majority of exposures that require PEP limits the ability to conduct randomized trials of different PEP regimens, durations of treatment, counseling protocols, and postregimen follow-up protocols.
Future Research Priorities
Qualitative Research
Identification of barriers to accessing care is a key challenge in ensuring timely and appropriate prescription of PEP. Expert members of the GDG shared anecdotal reports of settings Abbreviations: 3TC, lamivudine; ABC, abacavir; ARV, antiretroviral; ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; EFV, efavirenz; FTC, emtricitabine; HIV, human immunodeficiency virus; LPV/r, ritonavir-boosted lopinavir; NVP, nevirapine; PEP, postexposure prophylaxis; PrEP, preexposure prophylaxis; RAL, raltegravir; RCT, randomized controlled trial; STD, sexually transmitted disease; TDF, tenofovir disoproxil fumarate; WHO, World Health Organization; ZDV, zidovudine. a This recommendation appears in the WHO 2013 Antiretroviral Therapy Consolidated Guidelines and was adopted for the PEP guidelines. where healthcare workers were reluctant to prescribe PEP and concluded that there was a wide-scale lack of knowledge of the benefits of PEP among healthcare workers. Identification of the knowledge, attitudes, and prescription practices of PEP providers with associated documentation of the care experiences of PEP recipients would require survey-and interview-driven research. Formulation of appropriate comparative questions and evidence-based recommendations regarding the factors required to optimize delivery and receipt of PEP in the future would only be possible once such baseline data were available. Social desirability bias might limit the ability to be confident that provider self-reports would mirror clinical practice.
Global Registry
Ideally, evidence to inform guidelines of interventions should be based on data obtained from RCTs. Yet alternative study designs must be considered when there are ethical, statistical, and practical challenges to the feasibility of conducting an RCT as outlined in Table 1 . Given that PEP is provided across many and varied settings and PEP provision and uptake is generally low, the GDG recommended that a global PEP registry be established to standardize data reporting, to record toxicities due to PEP, to help inform future PEP drug regimen choice for both adults and children, and to potentially also provide information to track followup and linkage to care. Registries have already been established for other HIV research questions for which RCTs are not possible [5] , notably drug safety in pregnancy, and data generated from such registries have directly informed WHO guidance [6] .
RCTs of Adherence Strategies
Alternative methods of adherence support were considered in the WHO 2013 antiretroviral therapy guidelines [7] , and several of these may be suitable to PEP (such as peer support, alarms, text messaging, phone calls, and calendars), but the effectiveness of these interventions for HIV-uninfected individuals in the context of PEP has not been evaluated. At the same time, it is recognized that adherence research is notoriously difficult owing to the small event-rate differences, limiting the ability of any single trial to show significant differences [8] . Future efforts to identify interventions to improve adherence to PEP should therefore be informed by HIV treatment and other medication adherence research and lessons learned from similar interventions, including, for example, PrEP [9] , oral contraception, and the management of hypertension, and treatment of latent tuberculosis infection.
The Special Case of PEP to PrEP When PEP was first recommended for the prevention of occupational HIV exposures [10] , the presumption was that exposures were not intentional and would be infrequent. The recognition of settings of sexual assault, condom failure, and discovery that a partner was HIV infected after exposure led to the development of recommendations for the use of comparable regimens for nonoccupational PEP [11] . Subsequent studies found that some nonoccupational PEP users presented more than once, and a subset became recurrent users [12] . With the subsequent determination that the preexposure use of antiretrovirals could significantly decrease HIV incidence (PrEP) [13] , it is clear that a subset of people presenting for PEP could benefit from PrEP [14] . Because many PEP users may not be at recurrent risk, new research studies are needed to assist front-line PEP providers to efficiently determine which PEP users could benefit by transitioning to PrEP. Many of the nuances of optimal management are discussed in the article by Jain et al in this supplement [15] , but further research is warranted, given the newness of PrEP and the lack of a sufficient evidence base to suggest best practices.
Strengths and Limitations of the GRADE Approach to Prioritize Research
The structure and direction of the GRADE framework provided a useful starting point for the GDG discussions of future research priorities. Low-quality evidence is the first and most powerful indicator of the need for future and/or more robust research to underpin recommendations. The strength of a recommendation can also be informative, with conditional recommendations generally indicating the need for further research compared with recommendations rated as strong. However, several WHO guidelines have included strong recommendations based on low-quality evidence [16] . Three of the recommendations in these PEP guidelines are strong in the absence of high-quality evidence. These include the recommendation for a full 28-day prescription of antiretrovirals for HIV PEP following initial risk assessment (rated as very low quality); the recommendation for zidovudine (ZDV) plus lamivudine (3TC) as the preferred backbone for HIV PEP in children aged ≤10 years and that abacavir plus 3TC or tenofovir disoproxil fumarate (TDF) plus 3TC (or emtricitabine [FTC] ) can be considered as alternative regimens (rated as low quality); and the recommendation that TDF plus 3TC (or FTC) is the preferred backbone regimen for HIV PEP in adults and adolescents (rated as low to moderate quality). This apparent contradiction between strength and ratings reflects that factors such as values, preferences, and resource utilization can drive the strength of the recommendation in addition to the quality of evidence. Several clinical and programmatic questions were identified directly from the PEP clinical management pathway based on expert opinion gathered together in the GDG. We believe that positioning these questions within the GRADE framework will facilitate future revisions of the PEP guidelines given that the key questions in association with the required study design are well articulated, and can be addressed as new data emerge.
